Generic Name: pertuzumab
Brand Name: Perjeta
Manufacturer: Hoffmann-La Roche Limited
Therapeutic Area: Early stage breast cancer
Indications: Perjeta in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).
Manufacturer Requested Reimbursement Criteria1: Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive). Patients should receive neoadjuvant treatment with pertuzumab in combination with trastuzumab and chemotherapy for three to six cycles depending on the regimen chosen. Patients who start pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant setting and do not have residual disease following surgery should continue to receive adjuvant trastuzumab to complete one year of HER2-directed therapy.
Submission Type: Initial
Tumour Type: Breast
Project Status: Pending
Call for patient/clinician input open: March 16, 2021
Call for patient/clinician input closed: May 7, 2021
Anticipated Date: April 14, 2021
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.